Role of Alpelisib in HR-Positive PIK3CA-Mutated Advanced Breast Cancer

The standard of care for patients with advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast is endocrine therapy with or without a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor. Despite improvements in patient outcomes, a majority of patients eventually develop acquired resistance to endocrine-based therapy that is challenging to treat. […]

Read More

TMB Predicts Efficacy of Immune Checkpoint Inhibitors in MSI-H mCRC

Microsatellite instability (MSI) is a recognized biomarker of response to immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC). However, not all MSI-H patients respond to ICIs, indicating a need for additional biomarkers. In many cancers, tumor mutation burden (TMB) has been shown to be associated with response to immunotherapy, regardless of MSI status or […]

Read More

Presence of Oral HPV After Treatment of HNSCC May Predict Recurrence

An increasing number of patients with oropharyngeal head and neck squamous cell carcinoma (HNSCC) have human papillomavirus (HPV) associated cancer. Although HPV-positive oropharyngeal cancers are generally less aggressive than HPV-negative tumors, around 20% of HPV-positive patients experience cancer progression and death within 5 years. Thus, markers to identify patients at risk for recurrence are needed. […]

Read More

Consensus Molecular Subtypes Predict Outcomes in Patients With mCRC

Adoption of personalized treatment approaches in metastatic colorectal cancer (mCRC), which takes into consideration factors such as primary tumor location, RAS mutation status, and presence of microsatellite instabilities (MSI) for treatment selection, combined with an increased number of treatment options, has led to significant improvements in survival. However, the prognosis of patients with mCRC generally […]

Read More

New FDA Cancer Indications Approved in March and April

Atezolizumab Becomes First Immunotherapy Approved for Breast Cancer. The United States Food and Drug Administration (FDA) granted accelerated approval to the combination of the PD-L1 inhibitor atezolizumab (Tecentriq®, Genentech) and nab-paclitaxel for treatment of patients with PD-L1-positive (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥1% of the tumor area) advanced triple-negative breast […]

Read More

Single-Fraction SBRT Standard of Care for Painful Bone Metastases

Bone is a common metastatic site of advanced cancer. Durable pain control is a major goal of palliative care and important for maintaining quality of life cancer patients. Radiotherapy is the primary method for palliation of painful bone metastases, but there is no consensus regarding optimal dose and fractionation. Although no differences in pain relief […]

Read More

Interesting Articles Worth Reading

New Multiple Myeloma Treatment Guidelines. In recent years, several novel agents from across multiple lines of therapy have emerged for management of multiple myeloma. To aid physicians in evaluating new data and selecting the best treatment from a variety of options, the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario released updated treatment […]

Read More

Outcomes After Anti-PD-1 Therapy Discontinuation in Melanoma

The introduction of immune checkpoint inhibitors such as anti-PD-1 monoclonal antibodies radically altered the treatment paradigm for advanced melanoma, from a disease with limited treatment options and short survival to one in which durable responses and long-term survival can be achieved. While PD-1 inhibitors have become an essential component of melanoma treatment, little is known […]

Read More

Pembrolizumab Consolidation Active in Hodgkin Lymphoma Posttransplant

For patients with relapsed/refractory classical Hodgkin lymphoma who responded to salvage chemotherapy, autologous stem cell transplant (ASCT) remains the gold standard of treatment. While this may result in cure for some patients, up to half will relapse, and treatments following relapse are associated with short survival. However, results from a phase III AETHERA study demonstrated […]

Read More

ALK Resistance Mutations May Predict Efficacy of Lorlatinib in NSCLC

Treatment of patients with advanced non-small cell lung cancer (NSCLC) who harbor anaplastic lymphoma kinase (ALK) gene rearrangements is rapidly evolving and includes different ALK-targeting tyrosine kinase inhibitors (TKIs). Currently five ALK TKIs are approved by the FDA, including the first-generation TKI crizotinib, the second-generation TKIs alectinib, brigatinib, and ceritinib, and the third generation lorlatinib. […]

Read More